The stock of Journey Medical Corp (NASDAQ: DERM) has increased by 0.85% when compared to last closing price of $7.04. Despite this, the company has experienced a 1.43% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-24 that SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution.
Is It Worth Investing in Journey Medical Corp (NASDAQ: DERM) Right Now?
The 36-month beta value for DERM is also noteworthy at 0.81. There are mixed opinions on the stock, with 3 analysts rating it as a “buy”, 1 rating it as “overweight”, 0 rating it as “hold”, and 0 rating it as “sell”.
The public float for DERM is 8.89M, and at present, short sellers hold a 6.18% of that float. The average trading volume of DERM on July 04, 2025 was 133.32K shares.
DERM’s Market Performance
DERM stock saw a decrease of 1.43% in the past week, with a monthly decline of -1.39% and a quarterly a decrease of 13.78%. The volatility ratio for the week is 5.19%, and the volatility levels for the last 30 days are 5.65% for Journey Medical Corp (DERM). The simple moving average for the past 20 days is 2.39% for DERM’s stock, with a 23.20% simple moving average for the past 200 days.
Analysts’ Opinion of DERM
Many brokerage firms have already submitted their reports for DERM stocks, with Rodman & Renshaw repeating the rating for DERM by listing it as a “Buy”. The predicted price for DERM in the upcoming period, according to Rodman & Renshaw is $9 based on the research report published on August 22, 2024 of the previous year 2024.
ROTH MKM, on the other hand, stated in their research note that they expect to see DERM reach a price target of $11. The rating they have provided for DERM stocks is “Buy” according to the report published on June 28th, 2024.
DERM Trading at 0.47% from the 50-Day Moving Average
After a stumble in the market that brought DERM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.93% of loss for the given period.
Volatility was left at 5.65%, however, over the last 30 days, the volatility rate increased by 5.19%, as shares sank -4.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.92% lower at present.
During the last 5 trading sessions, DERM rose by +1.43%, which changed the moving average for the period of 200-days by +37.60% in comparison to the 20-day moving average, which settled at $6.93. In addition, Journey Medical Corp saw 32.22% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DERM starting from Maraoui Claude, who sold 4,834 shares at the price of $6.84 back on May 02 ’25. After this action, Maraoui Claude now owns 2,348,313 shares of Journey Medical Corp, valued at $33,065 using the latest closing price.
Benesch Joseph, the CFO of Journey Medical Corp, sale 2,409 shares at $6.84 during a trade that took place back on May 02 ’25, which means that Benesch Joseph is holding 203,557 shares at $16,478 based on the most recent closing price.
Stock Fundamentals for DERM
Current profitability levels for the company are sitting at:
- -0.12% for the present operating margin
- 0.66% for the gross margin
The net margin for Journey Medical Corp stands at -0.15%. The total capital return value is set at -0.15%. Equity return is now at value -48.14%, with -10.96% for asset returns.
Based on Journey Medical Corp (DERM), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at 1.17. The interest coverage ratio of the stock is -2.27.
Currently, EBITDA for the company is -8.4 million with net debt to EBITDA at -2.86. When we switch over and look at the enterprise to sales, we see a ratio of 3.01. The receivables turnover for the company is 3.12for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.34.
Conclusion
In summary, Journey Medical Corp (DERM) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
